Takeda Pharmaceutical Co. Ltd. (TAK) financials: revenue, earnings and cash flow
Fiscal 2017–2026 + TTM · from SEC filings · data as of November 16, 2026
Summary
Takeda Pharmaceutical Co.’s revenue went from $15.5B in fiscal 2017 to $28.3B in fiscal 2026, growth of about 6.9% a year.
Net income in fiscal 2026 was -$956M, a net margin of -3.4%; the best year in this period was 2021 with $3.4B.
Over the twelve months to September 30, 2026, revenue was $29.4B and net income $256M.
Free cash flow was $3.9B in fiscal 2026 and positive in 10 of the 10 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.4B | $28.3B | $30.7B | $28.2B | $30.2B | $29.3B | $28.9B | $30.3B | $18.9B | $16.6B | $15.5B |
| Gross profit | — | — | $20.1B | $18.8B | $20.9B | $20.2B | $19.9B | $20.3B | $13.0B | $12.0B | $10.5B |
| Operating income | — | — | $2.3B | $1.4B | $3.7B | $3.8B | $4.6B | $925M | $2.1B | $2.3B | $1.4B |
| Net income | $256M | -$956M | $722M | $953M | $2.4B | $1.9B | $3.4B | $408M | $1.2B | $1.8B | $1.0B |
| EPS (diluted) | $0.08 | $-0.30 | $0.23 | $0.30 | $0.75 | $0.60 | $1.07 | $0.13 | $0.39 | $0.56 | $0.33 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | −7.8% | +8.7% | −6.7% | +3.2% | +1.6% | −4.8% | +60.2% | +13.8% | +7.4% | — |
Cash flow
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $5.5B | $6.5B | $7.1B | $4.7B | $7.3B | $9.2B | $9.1B | $6.2B | $3.0B | $3.5B | $2.3B |
| Capital spending | -$2.8B | -$2.6B | -$1.3B | -$1.2B | -$1.1B | -$1.0B | -$1.0B | -$1.2B | -$701M | -$630M | -$551M |
| Free cash flow | $2.7B | $3.9B | $5.7B | $3.6B | $6.3B | $8.2B | $8.1B | $5.0B | $2.3B | $2.9B | $1.8B |
| Dividends paid | $2.0B | $2.0B | $2.0B | $1.9B | $2.1B | $2.3B | $2.6B | $2.6B | $1.3B | $1.3B | $1.3B |
| Buybacks | — | — | $347M | $15M | $202M | $637M | $19M | $34M | $11M | $176M | $207M |
| Stock-based pay | — | — | — | — | — | — | — | — | — | — | — |
Balance sheet
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $2.6B | $2.6B | $3.0B | $4.0B | $7.0B | $8.7B | $5.9B | $6.3B | $2.8B | $2.9B |
| Debt | — | $30.2B | $30.2B | $32.0B | $32.9B | $35.7B | $41.8B | $46.9B | $51.9B | $9.3B | — |
| Equity | — | $46.4B | $46.4B | $48.1B | $47.7B | $46.7B | $46.7B | $43.5B | $46.8B | $18.8B | $17.4B |
| Total assets | — | $95.4B | $95.4B | $99.9B | $104.8B | $108.2B | $116.5B | $118.1B | $124.5B | $38.6B | — |
| Shares (diluted) | 3.17B | 3.21B | 3.16B | 3.16B | 3.16B | 3.16B | 3.16B | 3.16B | 3.16B | 3.16B | 3.16B |
Margins and returns
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | 65.5% | 66.5% | 69.1% | 69.0% | 68.9% | 66.9% | 68.9% | 72.0% | 67.7% |
| Operating margin | — | — | 7.5% | 5.0% | 12.2% | 12.9% | 15.9% | 3.0% | 11.3% | 13.7% | 9.0% |
| Net margin | 0.9% | -3.4% | 2.4% | 3.4% | 7.9% | 6.5% | 11.8% | 1.3% | 6.5% | 10.6% | 6.6% |
| FCF margin | 9.2% | 13.9% | 18.7% | 12.7% | 20.8% | 28.0% | 28.1% | 16.5% | 12.0% | 17.6% | 11.5% |
| ROIC | — | — | 1.8% | 1.4% | 3.9% | 3.5% | 4.1% | 0.8% | 1.7% | 7.0% | 6.4% |
| ROE | — | — | 1.6% | 2.0% | 5.0% | 4.0% | 7.3% | 0.9% | 2.6% | 9.4% | 5.9% |
Frequently asked questions
What is Takeda Pharmaceutical Co.’s annual revenue?
$28.3B in fiscal 2026 and $29.4B over the twelve months to September 30, 2026.
How much profit does Takeda Pharmaceutical Co. make?
Net income was -$956M in fiscal 2026 (net margin -3.4%).
Is Takeda Pharmaceutical Co.’s revenue growing?
No: revenue fell 7.8% in fiscal 2026 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.